2021 is set to be a crucial year for Australia's medical cannabis industry as new products hit the market and patient numbers rise.

Click here to read the previous Australian cannabis outlook.

Australia’s cannabis market is moving along as regulations fall into place for sector expansion.

Under the current rules, the market may appear to be at a standstill, but recent approvals show there is momentum for a vibrant medical cannabis industry that will carry on in 2021.

Even though companies on the ground don’t expect to see recreational use become legal next year, Australia’s medical cannabis market is still expected to continue ahead with stronger numbers.

Here the Investing News Network (INN) offers some key points on what may be ahead for the Australian cannabis market in 2021, with insight from expert market watchers.

Australian cannabis outlook 2021: Medical still responsible for growth

As part of its Oceania Cannabis Report: Second Edition, international drug research firm Prohibition Partners indicates that the entire cannabis industry in Oceania is expected to be worth US$1.55 billion by 2024, with medical cannabis accounting for approximately 40 percent of that amount.

“Let’s build a very successful business based on medicinal cannabis … we’ve got to ride the global wave of global acceptance,” Brett Schwarz, CFO and corporate advisor with privately held firm Cannatrek, told INN.

Schwarz explained that it’s hard to project when exactly Australia may legalise recreational use, a key catalyst for the development of a cannabis market.

“We will one day, but we can’t say whether it’s in one year or five years,” said Schwarz. “There are more politicians talking about it, there are more doctors talking about it — that I think that it will come in time.”

The Cannatrek executive was cautious about expecting recreational cannabis to open anytime soon, instead opting to place his emphasis on what’s ahead for the medical market.

A study from FreshLeaf Analytics pegs Australian medical market sales at AU$95 million in 2020.

“Australia is a maturing market — not mature, but maturing, and I think the patients are seeing that, so they’re feeling more comfortable,” Schwarz said.

In the Prohibition Partners report, Roby Zomer, co-founder, managing director and CEO of MGC Pharma (ASX:MXC,OTC Pink:MGCLF), states that more education is driving up patient interest in cannabis; meanwhile, medical professionals are becoming more comfortable prescribing it.

“This is not only driving legislation change around the world, but driving demand for quality medicinal cannabis products,” the MCG Pharma executive said.

The growth trajectory is clear to see for medical cannabis in Australia. According to FreshLeaf Analytics, product availability rose quickly in the latter half of 2020 with 150 items now available for patients.

The research firm also indicates that at the end of 2020 there were 30,000 registered patients allowed to purchase medical cannabis in the country.

“Recent price decline has brought the illegal and legal markets to parity and has put us in line, from a pricing perspective, with more mature markets such as Canada,” the study explains.

Australian cannabis outlook 2021: CBD set for new year push

In December, the Therapeutic Goods Administration (TGA) gave the green light for low-dose cannabidiol (CBD) to become available through over-the-counter methods without a prescription. The Australian regulatory agency is in charge of the rules for medical cannabis.

In the document, the TGA indicates that this new ruling will officially come into effect in February.

“That’s very exciting, that’s the maturity,” Schwarz told INN about the TGA approval.

Any CBD products will need to be approved by the TGA and make it into the Australian Register of Therapeutic Goods. According to the regulatory agency, no products have yet been added.

Althea Group Holdings (ASX:AGH) CEO Josh Fegan said his company was glad to see the TGA’s decision to allow these products for sale over the counter, and also to increase the maximum recommended daily dose.

“This decision provides confirmation of that marketplace,” Fegan said; he confirmed that his firm will be working to make products available through this ruling.

Australian cannabis outlook 2021: Investor takeaway

Investors in the Australian cannabis market have watched the sector slowly develop over time.

Thanks to an expanding medical market, the industry has much to look forward to. What’s more, the growing potential for international exports has become available to companies as well.

Schwarz told INN cannabis companies in the country want to prove that their operations can serve Australia even as this international opportunity follows closely behind — he explained that his firm specifically is eyeing exports to Europe and throughout Asia.

As companies continue to expand according to market needs, growing pains could be expected as marijuana players set themselves up to capitalise on patient growth in Australia. But overall the sentiment from key players is that the future looks bright for cannabis in the country.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Australia Mining Update: H1 2021 in Review

Click here to read the previous Australia mining update.

After an uncertain 2020 for the Australian mining industry, the resource market showed signs of a sharp recovery in the first six months of the new year.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

Investing in Lithium in Australia

After the country became the world’s largest lithium producer in 2018, many market participants are wondering if investing in lithium in Australia is a good option

Without a doubt, the energy revolution is here to stay, with forecasts for electric vehicle (EV) sales increasing every day. As a result, demand for lithium, a key element in the lithium-ion batteries used to power electric cars, is expected to triple by 2025 — reaching about 1 million tonnes in size.

Keep reading... Show less

How to Buy Bitcoin in Australia

Investors looking for decentralised assets (and potentially major gains) in a post-COVID-19 Australia are turning in droves to cryptocurrencies.

Bitcoin in particular is getting Aussies excited after its price hit record highs in March 2021, and again the next month. As a finite resource, its volatility is proving exciting for many market watchers.

For those interested in jumping into the space, the Investing News Network has put together a step-by-step guide on how to start buying bitcoin in Australia — and how to stay safe while doing so.

Keep reading... Show less

Nickel Stocks in Western Australia

Nickel gets a lot of love these days. Besides its applications as a base metal, it's discovering a rising popularity as an electric vehicle metal thanks to its role in battery technology.

Nickel is a vital component in lithium-ion batteries, which are seeing "hockey stick"-like production rates around the world as electric vehicles become more prevalent.

According to the Australian government, the country holds around 19.7 million tonnes in economic demonstrated reserves of the metal, making it a top nation for nickel reserves, as well as a top nation for nickel production with 180,000 tonnes produced in 2019.

Keep reading... Show less

Medlab Clinical Ltd Executes Master Services Agreement with WEP Clinical Ltd

Sydney, Australia (ABN Newswire) – Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement (MSA) with WEP Clinical Ltd (WEP) for the exclusive development and delivery of Named Patient Programmes relating to the unlicensed supply of its proprietary NanaBis(TM) and NanoCBD(TM) to patients in the UK and Europe.

This Master Services Agreement is the first partnership for Medlab to supply their cannabinoid medications outside of its current Australian Special Access Scheme.

Dr Sean Hall, CEO of Medlab stated, “This is a major milestone for Medlab to begin supplying NanaBis(TM) and NanoCBD(TM) on prescription for the first time to patients outside Australia.”

Keep reading... Show less

When Will Australia Legalise Recreational Cannabis?

Recreational cannabis remains illegal in all Australia’s states and territories with the exception of the Australian Capital Territory (ACT). But could that change in the future?

So far there are no clear indicators as to when or if Australia could legalise recreational cannabis, but attitudes seem to be changing. Public support is growing, and there’s even some political acceptance.

Read on to learn more about when Australia may legalise recreational cannabis.

Keep reading... Show less

A State-by-State Guide to Cannabis in Australia

Australia made waves when it federally legalised medicinal cannabis in 2016, and its marijuana market has experienced significant growth since then.

A study from FreshLeaf Analytics pegs Australian medical market sales at AU$95 million in 2020, while research firm Prohibition Partners indicates that Oceania’s cannabis industry is expected to be worth US$1.55 billion by 2024; medicinal cannabis is expected to account for 40 percent of the industry.

Despite that growth, the country’s cannabis industry is still young. Recreational use is not yet in sight, and even medical access remains limited and highly regulated.

Keep reading... Show less

Australian Cannabis: Forecasts, Analysis and Expert Advice

Are you ready to start investing in Australia’s growing cannabis market?

Dive right in with our FREE Special Report, Australian Cannabis: Forecasts, Analysis and Expert Advice

Keep reading... Show less

Cannabis in the ACT: The Market a Year Post-Legalisation

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Top News

Related News